TerSera Therapeutics real-world ziconotide data at ASPN 2025 shows rising guideline-based intrathecal pain therapy adoption

Why are institutional investors tracking TerSera Therapeutics’ ziconotide real-world study presented at ASPN 2025 and what does it reveal about guideline-aligned intrathecal pain treatment trends?

TerSera Therapeutics LLC, a biopharmaceutical developer specializing in oncology, rare diseases, and non-opioid pain therapies, has captured investor attention after presenting new real-world evidence on intrathecal ziconotide prescribing trends at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) in Miami, Florida. The company, known for advancing therapies in severe chronic pain, unveiled the data through a poster session led by Dr. Tolga Suvar, Assistant Professor in the Department of Anesthesiology and Pain Medicine at Rush University Pain Center.

The retrospective, non-interventional study was conducted in collaboration with Pentec Health Inc., a specialty infusion pharmacy and home-based clinical services provider. It analyzed treatment patterns in more than 1,000 patients receiving ziconotide therapy between 2017 and 2024. The findings, which compared real-world clinical use to Polyanalgesic Consensus Conference (PACC) guidelines, revealed a marked increase in adherence to recommended dosing and monotherapy strategies.

For institutional investors and analysts, the results are significant because they highlight the growing clinical confidence in PRIALT® (ziconotide intrathecal infusion) as a non-opioid pain management option. This trend is viewed as an indicator of potential market expansion, especially given the ongoing shift away from opioid-based pain therapies.

How have ziconotide prescribing patterns evolved in real-world clinical practice according to the TerSera Therapeutics ASPN 2025 study?

The study demonstrated three major shifts in prescribing patterns for ziconotide, indicating closer alignment with established pain management guidelines. First, ziconotide monotherapy use increased significantly, rising from 36.0% in 2017–2018 to 63.1% in 2023–2024. This shift underscores a growing preference among pain specialists for using the drug independently, consistent with PACC recommendations, rather than in combination with other intrathecal agents.

Second, there was a notable move toward more conservative initial dosing strategies. The proportion of patients starting therapy with lower ziconotide doses (<0.5 mcg/day) increased from just 3.4% at the beginning of the study period to 20.3% in recent years. Clinicians are increasingly opting for patient-tailored approaches, recognizing that gradual titration reduces the risk of adverse neuropsychiatric effects associated with higher starting doses.

Third, the adoption of patient-controlled analgesia (PCA) techniques nearly doubled during the study period, with use rising from 23.7% to 45.3%. The increased implementation of PCA reflects growing clinical interest in allowing patients to manage breakthrough pain episodes more effectively, improving overall quality of life while maintaining stable basal dosing.

Dr. Suvar emphasized that the study underscores the importance of real-world evidence in refining pain management protocols. By showing increased alignment with PACC guidelines, the findings reinforce the perception that ziconotide therapy is becoming more standardized, data-driven, and individualized.

What does the data reveal about TerSera Therapeutics’ positioning in the non-opioid pain management market?

The real-world data presented at ASPN 2025 positions TerSera Therapeutics as a key player in the evolving non-opioid pain management landscape. Ziconotide’s unique mechanism of action—derived from marine snail peptide and acting as a selective N-type calcium channel blocker—differentiates it from opioid-based treatments. The drug is indicated for severe chronic pain in patients intolerant of, or refractory to, conventional systemic analgesics or intrathecal morphine.

For institutional investors, this differentiation is crucial. Analysts monitoring the chronic pain market view TerSera Therapeutics as well positioned to benefit from regulatory and clinical shifts favoring non-opioid alternatives. The growing clinical adoption of conservative dosing and monotherapy use may also expand ziconotide’s potential patient pool by reducing concerns about psychiatric or cognitive side effects.

Pentec Health’s role in facilitating large-scale data collection adds further credibility to the findings, as the company is one of the leading specialty infusion pharmacy providers in the United States. Its national network and patient management infrastructure suggest scalability for ziconotide adoption if guideline-aligned practices continue to grow.

How is institutional sentiment shaping around TerSera Therapeutics’ chronic pain portfolio following ASPN 2025?

Institutional sentiment around TerSera Therapeutics has been cautiously optimistic following the ASPN 2025 presentation. While the company remains a private biopharmaceutical developer, investors with stakes in specialty pain management are closely monitoring real-world ziconotide adoption as a proxy for broader market momentum in non-opioid analgesics.

Analysts have highlighted that guideline-aligned prescribing practices generally correlate with improved clinical outcomes and broader payer acceptance. As insurers increasingly prioritize evidence-based therapies, drugs with growing real-world adoption—such as PRIALT—may experience more favorable reimbursement dynamics.

Furthermore, the increasing use of PCA and low-dose titration strategies is viewed as a positive signal for long-term adherence and patient satisfaction, two critical factors for sustaining commercial growth in the intrathecal pain segment.

What safety considerations continue to impact clinical use of ziconotide despite increased adoption trends?

Despite the positive trends, ziconotide’s adoption is still shaped by well-documented safety considerations. The drug carries a boxed warning for neuropsychiatric adverse reactions, including confusion, hallucinations, and cognitive impairment, which require frequent monitoring. Clinical trials reported hallucinations in 12% of patients and cognitive impairment in up to 33%, although most effects are reversible upon dose adjustment or discontinuation.

The ASPN 2025 data indirectly reflect efforts to mitigate these risks through conservative dosing and patient-tailored titration. The increased use of lower starting doses and gradual upward titration appears to be clinicians’ primary strategy for balancing efficacy with safety.

Additionally, strict aseptic procedures are critical due to the risk of meningitis associated with intrathecal microinfusion devices. Institutional adoption will likely remain contingent on continued training for healthcare providers and vigilance in managing device-related infections.

What is the future outlook for TerSera Therapeutics’ PRIALT adoption and its role in chronic pain management strategies?

Looking ahead, analysts expect TerSera Therapeutics to continue positioning PRIALT as a guideline-driven, non-opioid alternative for complex chronic pain cases. With increasing real-world evidence supporting safe and effective use under conservative dosing protocols, institutional investors anticipate further integration of ziconotide into mainstream pain management algorithms.

Future growth prospects may also depend on additional research partnerships similar to the Pentec Health collaboration. Real-world evidence studies play a crucial role in payer negotiations, as insurers seek concrete outcomes data to justify reimbursement for specialty pain management therapies.

Moreover, as U.S. pain specialists seek alternatives amid ongoing opioid litigation and prescribing restrictions, PRIALT’s differentiation as a non-addictive intrathecal analgesic may provide TerSera Therapeutics with a competitive edge. Analysts predict that further publications and long-term outcome data could strengthen clinical confidence, potentially expanding the patient population eligible for intrathecal therapy.